Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06283979 · ClinicalTrials.gov registry record · Phase 2
A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.
A Phase 2 study of Osteomyelitis and Pressure Ulcer, Stage IV, sponsored by Biocomposites.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 7
- Study locations
NCT06283979 is a Phase 2 study of Osteomyelitis and Pressure Ulcer, Stage IV that is actively recruiting participants, run by Biocomposites. The registered enrollment target is 60 participants, below the 308-participant average among 4 other Osteomyelitis trials with a reported enrollment target (81% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT06283979, a Phase 2 study of Osteomyelitis and Pressure Ulcer, Stage IV, is actively recruiting participants, sponsored by Biocomposites.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this trial is to assess the safety, tolerability and between-group effect size of STIMULAN VG (with debridement) and a course of systemic antibiotics to standard of care (debridement and systemic antibiotics only) for the treatment of osteomyelitis associated stage IV pressure ulcers.
Conditions Studied
Interventions
- PROCEDURE Standard of Care
- COMBINATION_PRODUCT STIMULAN VG
Study Locations (7)
Arizona
- Advanced Foot Care, LLC - Phoenix
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
Mississippi
- University of Mississippi Medical Center - Jackson
Missouri
- Missouri Orthopaedic Institute - Columbia
Nebraska
- University of Nebraska Medical Center - Omaha
New York
- NYU Langone Hospital - Long Island Clinical Research Center - Mineola
Pennsylvania
- University of Pittsburgh, McGowan Institute for Regenerative Medicine - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-06-15 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06283979
The ClinicalTrials.gov registry entry for NCT06283979 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 308-participant average among 4 other Osteomyelitis trials with a reported enrollment target (81% lower). The listed sponsor is Biocomposites, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Osteomyelitis appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT06283979 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Arizona, Illinois, Mississippi.
Frequently Asked Questions
What is clinical trial NCT06283979 about?
NCT06283979 is a clinical study titled "A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.". The purpose of this trial is to assess the safety, tolerability and between-group effect size of STIMULAN VG (with debridement) and a course of systemic antibiotics to standard of care (debridement and systemic antibiotics only) for the treatment of osteomyelitis associated stage IV pressure ulcers.
What is the current status of trial NCT06283979?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-06-15. Estimated completion is 2026-12-01.
What conditions does trial NCT06283979 study?
This clinical trial studies the following conditions: Osteomyelitis, Pressure Ulcer, Stage IV.
What interventions are being tested in trial NCT06283979?
The interventions under investigation include: Standard of Care (PROCEDURE), STIMULAN VG (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06283979?
This trial is sponsored by Biocomposites, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06283979 being conducted?
This trial has 7 study locations across Arizona, Illinois, Mississippi, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteomyelitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Retention and Re-Engagement in Treatment for Addiction Following Serious Injection Related Infections (RETAIN)
RECRUITING · NA
-
Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC)
ACTIVE NOT RECRUITING · NA
-
UT Southwestern Diabetic Foot Ulcers (DFU) and Osteomyelitis (DFO) Recruitment Database, Data and Tissue Repository
COMPLETED
-
Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.